NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Abogen Biosciences

Abogen Biosciences

Private
SuzhouHealthcare & Life Scienceshttps://abogenbio.com/

Last Round

Grant

Feb 4, 2026

Est. Valuation

$3.1B

Total Funding Raised

$1.13B

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Abogen Biosciences is a biotechnology company that develops mRNA-based therapeutics and vaccines for infectious diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

mRNA therapeuticsmRNA vaccineslipid nanoparticle deliveryLNP deliveryimmuno-oncologycancer immunotherapyinfectious disease vaccinesplatform biotechthermostable vaccinescircular RNAcircRNAdrug discovery platformnucleic acid therapeuticsRNA therapeuticsgenetic medicinesautoimmune diseasesclinical-stage biotechAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abogen Biosciences Comparables

Compare Abogen Biosciences with similar companies based on industry and business-model similarity.

Abogen Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Suzhou CureMed Biopharma Technology Co., Ltd
86%
Stemirna Therapeutics
85%
Innorna
83%

Abogen Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 4, 2026
Series C ExtensionNov 29, 2021
Series CAug 19, 2021
Series BApr 7, 2021
Series AOct 27, 2020

Key People

Founding team and executive leadership

Bo Y.

Chief Executive Officer

Executive Team

Tracy Song

Chief Financial Officer

Executive Team

Abogen Biosciences Investors

Notable investors and investment history

Abogen Biosciences investors
InvestorRounds
HighLight CapitalSeries C, Series B
Oriental Spring CapitalSeries C
Alwin CapitalSeries C
Jifeng VenturesSeries B
BioTrack CapitalSeries C, Series B
Youshan CapitalSeries C
Loyal Valley CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors grew 3841% MoM, reaching 2.7K.

  • Apr 21, 2026

    Phase I results for mRNA T-cell engager ABO2203 presented at AACR Annual Meeting.

Abogen Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Abogen Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Abogen Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range91
Year Founded2019
Last FundingFeb 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.